5 Key Takeaways
-
1
Dr. Jennifer I. Lim presented updates on wet age-related macular degeneration at the 2025 American Academy of Ophthalmology Annual Meeting.
-
2
Extension studies for Vabysmo and Eylea HD show maintained durability and stable best-corrected visual acuity over four years.
-
3
The PORTAL study indicates that switching to the Susvimo port delivery system maintains visual acuity and central subfield thickness reductions.
-
4
New treatments discussed include TH-103, which offers enhanced anti-VEGF activity and durability through improved binding mechanisms.
-
5
Dr. Lim also highlighted investigational agents such as TKIs, gene therapy, and zifibancimig for potential future use.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
